High-dose antioxidant administration is associated with a reduction in post-injury complications in critically ill trauma patients

Injury ◽  
2011 ◽  
Vol 42 (1) ◽  
pp. 78-82 ◽  
Author(s):  
Aviram M. Giladi ◽  
Lesly A. Dossett ◽  
Sloan B. Fleming ◽  
Naji N. Abumrad ◽  
Bryan A. Cotton
Keyword(s):  
Critically Ill ◽  
High Dose ◽  
Trauma Patients ◽  
Post Injury

First reported case of Weissella confusa abundance in the lung microbiota of a critically ill trauma patient with acute respiratory distress syndrome - caution warranted in the use of the Weissella genus as a probiotic

2020 ◽  
Author(s):  
Sandeep Chakraborty
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Critically Ill ◽  
Distress Syndrome ◽  
Joint Infection ◽  
Starter Cultures ◽  
Trauma Patients ◽  
Virulence Determinants ◽  
Prosthetic Joint

Weissella strains are currently being used for biotechnological and probiotic purposes [1]. While, Weissella hellenica found in flounder intestine had probiotic effects [2], certain species from this genus are opportunistic pathogens in humans. Apart from being implicated in disease in farmed rainbow trout [3], Weissella has been found to cause the following disease in humans.1. endocarditis [4,5]2. bacteraemia [6]3. prosthetic joint infection [7]Whole genome sequences ‘find several virulence determinants such as collagen adhesins, aggregation sub- stances, mucus-binding proteins, and hemolysins in some species’, as well as antibiotic resistance-encoding genes [8]. Caution is warranted in selecting of Weissella strains as starter cultures or probiotics, if at all, since the other option, Lactobacillus, are rarely involved in human disease.Here, the analysis of the lung microbiota in critically ill trauma patients suffering from acute respiratory distress syndrome [9] shows (Accid:ERR1992912) shows complete colonization of Weissella (Fig 1). While, the study mentions ‘significant enrichment of potential pathogens including Streptococcus, Fusobacterium, Prevotella, Haemophilus and Treponema’, there is no reference to the Weissella genus. The percentages of Weissella strains are :confusa=81, soli=7 ,hellenica=5 ,diestrammenae=2. I believe this is the first reported case of Weissella causing ARDS in humans.

scholarly journals Nonepileptic Myoclonus in COVID-19: Case Report

2021 ◽  
pp. 194187442110043
Author(s):  
Henly Hewan ◽  
Annie Yang ◽  
Aparna Vaddiparti ◽  
Benison Keung
Keyword(s):  
Case Report ◽  
Critically Ill ◽  
Recovery Phase ◽  
Critically Ill Patient ◽  
High Dose ◽  
The Novel ◽  
Neurological Manifestations ◽  
Immune Mediated ◽  
Novel Coronavirus ◽  
Post Infectious

In late 2019, the novel coronavirus, SARS-CoV-2, and the disease it causes, COVID-19, was identified. Since then many different neurological manifestations of COVID-19 have been well reported. Movement abnormalities have been rarely described. We report here a critically ill patient with COVID-19 who developed generalized myoclonus during the recovery phase of the infection. Myoclonus was associated with cyclical fevers and decreased alertness. Movements were refractory to conventional anti-epileptic therapies. There was concern that myoclonus could be part of a post-infectious immune-mediated syndrome. The patient improved fully with a 4-day course of high-dose steroids. Our experience highlights a rare, generalized myoclonus syndrome associated with COVID-19 that may be immune-mediated and is responsive to treatment.

scholarly journals Impact of high dose prophylactic anticoagulation in critically ill patients with COVID-19 pneumonia

CHEST Journal ◽  
2021 ◽  
Author(s):  
Charles Tacquard ◽  
Alexandre Mansour ◽  
Alexandre Godon ◽  
Julien Godet ◽  
Julien Poissy ◽  
...  
Keyword(s):  
Critically Ill ◽  
Critically Ill Patients ◽  
High Dose ◽  
Prophylactic Anticoagulation

Algorithm for assessing renal dysfunction risk in critically ill trauma patients receiving aminoglycosides

1990 ◽  
Vol 160 (5) ◽  
pp. 473-480 ◽  
Author(s):  
Bradley A. Boucher ◽  
Bridgett C. Coffey ◽  
David A. Kuhl ◽  
Elizabeth A. Tolley ◽  
Timothy C. Fabian
Keyword(s):  
Renal Dysfunction ◽  
Critically Ill ◽  
Trauma Patients

Burn Resuscitation

2018 ◽  
Author(s):  
Nicole Gibran ◽  
Samuel P Mandell ◽  
Theresa L. Chin
Keyword(s):  
Wound Care ◽  
Rescue Therapy ◽  
Initial Period ◽  
Total Body Surface Area ◽  
Inhalation Injury ◽  
Accurate Estimation ◽  
High Dose ◽  
Post Injury ◽  
Secondary Survey ◽  
Burn Resuscitation

Resuscitation of adult patients with burn size greater than 20% total body surface area (TBSA) and pediatric patients with burn size greater than 15% TBSA is essential for early survival due to the fluid shifts that occur after injury. After the primary and secondary survey, burn resuscitation is different from resuscitation from other types of shock because it is based on continuous fluid administration. Judicious use of fluids reduces fluid creep and complications of over-resuscitation. Accurate estimation of TBSA will improve the use of crystalloids. Furthermore, inhalation injury, chemical injury, electrical injury, and preexisting comorbidities can complicate resuscitation of these patients. Although crystalloids are the mainstay of therapy, adjuncts to resuscitation such as colloids, plasma exchange, and high-dose vitamin C have been considered to reduce complications of over-resuscitation or support patients who are refractory to typical resuscitation strategies in the initial period post injury. Wound care should never precede the primary and secondary survey and most often can wait until definitive care at a burn center. This review contains 5 figures, 6 tables and 54 references Key Words: burn, colloid, crystalloid, failing resuscitation, rescue therapy, resuscitation

Hypomagnesemia as a Predictor of Mortality in Critically Ill Trauma Patients

1995 ◽  
pp. 153-157
Author(s):  
Philip C. Wry ◽  
Anthony J. Mure ◽  
Steven E. Ross
Keyword(s):  
Critically Ill ◽  
Trauma Patients

scholarly journals High-dose vitamin C infusion for the treatment of critically ill COVID-19

2020 ◽  
Author(s):  
Jing Zhang ◽  
Xin Rao ◽  
Yiming Li ◽  
Yuan Zhu ◽  
Fang Liu ◽  
...  
Keyword(s):  
Placebo Group ◽  
Vitamin C ◽  
Critically Ill ◽  
Day Treatment ◽  
Invasive Mechanical Ventilation ◽  
Controlled Clinical Trial ◽  
High Dose ◽  
C 50 ◽  
Intravenous Vitamin ◽  
High Dose Vitamin

Abstract BackgroundNo specific medication has been proven effective for the treatment of patients with severe coronavirus disease 2019 (COVID-19). Here, we tested whether high-dose vitamin C infusion was effective for severe COVID-19.MethodsThis randomized, controlled clinical trial was performed at 3 hospitals in Hubei, China. Patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the ICU were randomly assigned in as 1:1 ratio to either the high-dose intravenous vitamin C (HDIVC) or the placebo. HDIVC group received 12 g of vitamin C/50 ml every 12 hours for 7 days at a rate of 12 ml/hour, and the placebo group received bacteriostatic water for injection in the same way. The primary outcome was invasive mechanical ventilation-free days in 28 days(IMVFD28). Secondary outcomes were 28-day mortality, organ failure, and inflammation progression.ResultsFifty-four critical COVID-19 patients were ultimately recruited. There was no difference in IMVFD28 between two groups. During the 7-day treatment period, patients in the HDIVC group had a steady rise in the PaO2/FiO2 (day 7: 229 vs. 151 mmHg, 95% CI 33 to 122, P = 0.01). Patients with SOFA scores ≥ 3 in the HDIVC group exhibited a significant reduction in 28-day mortality (P = 0.05) in univariate survival analysis. IL-6 in the VC group was lower than that in the placebo group (19.42 vs. 158.00; 95% CI -301.72 to -29.79; P = 0.04) on day 7.ConclusionThe addition of HDIVC may provide a protective clinical effect without any adverse events in critically ill patients with COVID-19.Clinicaltrial.gov identifer: NCT04264533

Sign in / Sign up

Export Citation Format

Share Document